drugset / Press release
Eyestem announces interim safety and efficacy data from ongoing Phase I trial using Eyecyte-RPE for the treatment of Geographic Atrophy patients, in an International Conference "The Future is Here II, Exploring New Frontiers of Ocular Research", organized by LV Prasad Eye Institute, Hyderabad b/w Jan 9-12.
2025-01-10 · Eyestem Research Pvt. Ltd. · original eyestem.com ↗
Exciting news for dry AMD Research! We are thrilled to share the groundbreaking Phase I data on Eyecyte-RPE stem cells for treating Geographic Atrophy due to Dry Age Related Macular Degeneration. The safety and efficacy results from six patients are outstanding, with an excellent safety profile observed. View Post
The release as fetched from its publisher. eyestem.com ↗